Shanu Modi

Department of Oncology, Memorial Sloan Kettering Cancer Center

Affiliated withMemorial Sloan Kettering Cancer Center

Research Area

Biography

Shanu Modi has not added Biography.
If you are Shanu Modi and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 12	2014

Other Publications

Article	Year
An update on epidermal growth factor receptor inhibitors. Current oncology reports\| PubMed ID: 11734113	2002
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast... Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 12202668	2002
Single-agent gemcitabine in the treatment of advanced breast cancer. Clinical breast cancer\| PubMed ID: 14754466	2004
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast cancer research and treatment\| PubMed ID: 15803362	2005
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clinical breast cancer\| PubMed ID: 15899073	2005
Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer\| PubMed ID: 16134178	2005
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer investigation\| PubMed ID: 16203655	2005
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clinical breast cancer\| PubMed ID: 16942645	2006
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 18048823	2007
Preoperative chemotherapy for breast cancer: miracle or mirage? JAMA\| PubMed ID: 18073362	2007
HER2 breast cancer therapies: a review. Biologics : targets & therapy\| PubMed ID: 19707416	2009
Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results. Clinical breast cancer\| PubMed ID: 20133256	2010
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 20421541	2010
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 21350003	2011
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 21558407	2011
Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs? Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 21730267	2011
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with ... Journal of clinical pharmacology\| PubMed ID: 21953571	2012
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochimica et biophysica acta\| PubMed ID: 22062686	2012
Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert opinion on drug discovery\| PubMed ID: 22400044	2011
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer\| PubMed ID: 22648179	2012
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib,... Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 22649126	2012
A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22781552	2012
HSP90 inhibitors for cancer therapy and overcoming drug resistance. Advances in pharmacology (San Diego, Calif.)\| PubMed ID: 22959035	2012
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 23092874	2012
Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer prevention research (Philadelphia, Pa.)\| PubMed ID: 23531446	2013
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Breast cancer research and treatment\| PubMed ID: 23580070	2013
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. Nuclear medicine communications\| PubMed ID: 24100444	2013
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clinical breast cancer\| PubMed ID: 24512858	2014
Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert opinion on investigational drugs\| PubMed ID: 24669860	2014
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 24799465	2014
Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology c... Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 24799487	2014
Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. Breast cancer research and treatment\| PubMed ID: 24929675	2014